PrakashS., WaleleA., DimkovicN., BargmanJ., VasS., OreopoulosD.G.Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.Perit Dial Int2001; 21: 290–5.
2.
SilverbergD.S., IainaA., PeerG., KaplanE., LeviB., FrankN.Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.Am J Kidney Dis1996; 27: 234–8.
3.
ChandlerG., HarchowalJ., MacdougallI.C.Intravenous iron hydroxysaccharate: establishing the optimum dose.J Am Soc Nephrol1997; 8: 217.
4.
MacdougallI.C.Intravenous administration of iron in epoetin-treated haemodialysis patients — which drugs, which regimen?Nephrol Dial Transplant2000; 15: 1743–5.
5.
VychytilA., Haag–WeberM.Iron status and iron supplementation in peritoneal dialysis patients.Kidney Int Suppl1999; 69: S71–8.
6.
BanyaiS., RainerV., DerflerK., DrumlW., HörlW.H., Sunder–PlassmannG.Bleomycin detectable free iron (BDI) is present in patients on intravenous iron therapy (Abstract).J Am Soc Nephrol1998; 9: 198A.
7.
BreuerW., ErmersM.J.J., PootrakulP., AbramowA., HershkoC., CabantchikZ.I.Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.Blood2001; 97: 792–8.
8.
HörlW.H.Should we still use iron dextran in hemodialysis patients?Am J Kidney Dis2001; 37: 859–61.
